Pfizer Inc
PFE25.680USD
-0.590-2.25%
Handelsschluss 10/08, 16:00（ET）Kurse um 15 Minuten verzögert
145.99BMarktkapitalisierung
13.58KGV TTM
mehr Informationen über Pfizer Inc Unternehmen
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.
Pfizer Inc Informationen
BörsenkürzelPFE
Name des UnternehmensPfizer Inc
IPO-datumJan 17, 1944
CEODr. Albert Bourla, Ph.D.
Anzahl der mitarbeiter81000
WertpapierartOrdinary Share
GeschäftsjahresendeJan 17
Addresse66 Hudson Boulevard East
StadtNEW YORK
BörseNYSE Consolidated
LandUnited States of America
Postleitzahl10001-2192
Telefon12127332323
Websitehttps://www.pfizer.com/
BörsenkürzelPFE
IPO-datumJan 17, 1944
CEODr. Albert Bourla, Ph.D.
Führungskräfte von Pfizer Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
372.89K
+10.54%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
161.04K
+8.26%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.94K
+8.23%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
70.77K
-0.78%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.46K
+149.67%
Ms. Lidia L. Fonseca
Ms. Lidia L. Fonseca
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
30.96K
--
Mr. Aamir Malik
Mr. Aamir Malik
Executive Vice President, Chief US Commercial Officer
Executive Vice President, Chief US Commercial Officer
29.55K
+7800.53%
Ms. Payal Sahni
Ms. Payal Sahni
Executive Vice President, Chief People Experience Officer
Executive Vice President, Chief People Experience Officer
24.85K
+6.62%
Mr. Cyrus Taraporevala
Mr. Cyrus Taraporevala
Independent Director
Independent Director
10.00K
--
Dr. Scott Gottlieb, M.D.
Dr. Scott Gottlieb, M.D.
Independent Director
Independent Director
10.00K
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
372.89K
+10.54%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
161.04K
+8.26%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.94K
+8.23%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
70.77K
-0.78%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.46K
+149.67%
Ms. Lidia L. Fonseca
Ms. Lidia L. Fonseca
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
30.96K
--
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Eliquis alliance revenues and direct sales
2.00B
13.67%
Vyndaqel family
1.61B
11.02%
Prevnar family
1.38B
9.44%
All other Hospital
1.09B
7.42%
Oncology-Ibrance
1.05B
7.16%
Andere
7.52B
51.29%
Nach RegionUSD
Name
Umsatz
Anteil
United States
8.89B
60.70%
Developed Markets
3.39B
23.16%
Emerging Markets
2.37B
16.15%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Eliquis alliance revenues and direct sales
2.00B
13.67%
Vyndaqel family
1.61B
11.02%
Prevnar family
1.38B
9.44%
All other Hospital
1.09B
7.42%
Oncology-Ibrance
1.05B
7.16%
Andere
7.52B
51.29%
Aktionärsstatistik
Aktualisiert: Fri, Aug 15
Aktualisiert: Fri, Aug 15
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.33%
State Street Global Advisors (US)
5.21%
BlackRock Institutional Trust Company, N.A.
5.08%
Geode Capital Management, L.L.C.
2.24%
Norges Bank Investment Management (NBIM)
1.65%
Andere
76.48%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.33%
State Street Global Advisors (US)
5.21%
BlackRock Institutional Trust Company, N.A.
5.08%
Geode Capital Management, L.L.C.
2.24%
Norges Bank Investment Management (NBIM)
1.65%
Andere
76.48%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
32.83%
Investment Advisor/Hedge Fund
22.82%
Research Firm
3.11%
Pension Fund
2.25%
Bank and Trust
1.84%
Sovereign Wealth Fund
1.75%
Hedge Fund
1.27%
Insurance Company
1.24%
Holding Company
0.05%
Andere
32.83%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
4787
3.82B
67.19%
-100.74M
2025Q2
4945
3.85B
67.75%
-89.09M
2025Q1
5074
3.86B
67.90%
-51.97M
2024Q4
5153
3.84B
67.74%
-83.26M
2024Q3
5005
3.85B
67.99%
-51.77M
2024Q2
5026
3.84B
67.75%
-120.77M
2024Q1
5032
3.89B
68.71%
-120.39M
2023Q4
5089
3.97B
70.25%
-96.67M
2023Q3
4952
4.00B
70.89%
-71.80M
2023Q2
4962
4.02B
71.16%
-62.35M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
530.68M
9.33%
+10.10M
+1.94%
Jun 30, 2025
State Street Global Advisors (US)
296.30M
5.21%
-669.22K
-0.23%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
288.89M
5.08%
-2.65M
-0.91%
Jun 30, 2025
Geode Capital Management, L.L.C.
127.47M
2.24%
+1.82M
+1.45%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
93.65M
1.65%
+5.87M
+6.68%
Jun 30, 2025
Wellington Management Company, LLP
77.00M
1.35%
-26.49M
-25.60%
Jun 30, 2025
MFS Investment Management
72.76M
1.28%
-276.04K
-0.38%
Jun 30, 2025
State Farm Insurance Companies
57.59M
1.01%
-158.70K
-0.27%
Jun 30, 2025
BlackRock Asset Management Ireland Limited
54.65M
0.96%
+4.18M
+8.29%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
49.17M
0.86%
+1.14M
+2.36%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Tue, Sep 2
Aktualisiert: Tue, Sep 2
Name
Anteil
Franklin US Dividend Booster Index ETF
128.98%
First Trust NASDAQ Pharmaceuticals ETF
7.17%
First Trust Morningstar Dividend Leaders Index Fund
6.24%
Amplify Weight Loss Drug & Treatment ETF
5.07%
Coastal Compass 100 ETF
4.82%
Invesco Pharmaceuticals ETF
4.82%
WBI Power Factor High Dividend ETF
4.75%
LSV Disciplined Value ETF
4.68%
Vaneck Durable High Dividend ETF
4.38%
iShares U.S. Pharmaceuticals ETF
4.28%
Mehr Anzeigen
Franklin US Dividend Booster Index ETF
Anteil128.98%
First Trust NASDAQ Pharmaceuticals ETF
Anteil7.17%
First Trust Morningstar Dividend Leaders Index Fund
Anteil6.24%
Amplify Weight Loss Drug & Treatment ETF
Anteil5.07%
Coastal Compass 100 ETF
Anteil4.82%
Invesco Pharmaceuticals ETF
Anteil4.82%
WBI Power Factor High Dividend ETF
Anteil4.75%
LSV Disciplined Value ETF
Anteil4.68%
Vaneck Durable High Dividend ETF
Anteil4.38%
iShares U.S. Pharmaceuticals ETF
Anteil4.28%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
44.91B
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Dec 12, 2024
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Mar 07, 2025 going ex on Jan 24, 2025
Jan 24, 2025
Mar 07, 2025
Jan 24, 2025
Oct 09, 2024
PFE.NB Final Cash Dividend of gross USD 0.42 paid on Dec 02, 2024 going ex on Nov 08, 2024
Nov 08, 2024
Dec 02, 2024
Nov 08, 2024
Jun 26, 2024
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Sep 03, 2024 going ex on Jul 26, 2024
Jul 26, 2024
Sep 03, 2024
Jul 26, 2024
Apr 24, 2024
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Jun 14, 2024 going ex on May 09, 2024
May 10, 2024
Jun 14, 2024
May 09, 2024
Dec 14, 2023
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Mar 01, 2024 going ex on Jan 25, 2024
Jan 26, 2024
Mar 01, 2024
Jan 25, 2024
Oct 04, 2023
PFE.NB Final Cash Dividend of gross USD 0.41 paid on Dec 04, 2023 going ex on Nov 09, 2023
Nov 10, 2023
Dec 04, 2023
Nov 09, 2023
Jun 22, 2023
PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Sep 05, 2023 going ex on Jul 27, 2023
Jul 28, 2023
Sep 05, 2023
Jul 27, 2023
Apr 26, 2023
PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Jun 09, 2023 going ex on May 11, 2023
May 12, 2023
Jun 09, 2023
May 11, 2023
Dec 09, 2022
PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Mar 03, 2023 going ex on Jan 26, 2023
Jan 27, 2023
Mar 03, 2023
Jan 26, 2023
Sep 22, 2022
PFE.NB Final Cash Dividend of gross USD 0.4 paid on Dec 05, 2022 going ex on Nov 03, 2022
Nov 04, 2022
Dec 05, 2022
Nov 03, 2022
Mehr Anzeigen
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
